OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease Full enrollment achieved on September 6th with a total of 240 patients enrolled in studyTop-line data planned for release in December 2023Phase 2 trial is designed as a potential registration trial,...

OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”) Full enrollment anticipated by first week of SeptemberOKYO on schedule to release top-line data before end of 2023Phase 2 trial is designed as potential registration trial with pre-specified primary...

OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease Trial designed with a two-week run-in period to reduce the well-known placebo effect in trials involving pain componentTop-line data from trial anticipated in Q4, 2023 LONDON and NEW YORK, June 06,...